AbbVie writes off $3.5B on Cerevel drug after Phase 2 failures
AbbVie is taking a major loss in the wake of its Cerevel buyout.
AbbVie said it will write off $3.5 billion following two mid-stage failures …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
